MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has revealed plans to conduct an underwritten public offering of common stock ...

The proceeds of the Loan are to be used for accounts payable and for general working capital purposes.

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

Food - Other Distribution: National See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA) ...

Food - Microbial contamination - E. Coli - other pathogenic Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA) ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, in the treatment and prevention of acute brain and nerve injuries.

Annovis Bio Inc., a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

Last year was a big year for Fairbanks Museum, highlighted by major moments in the museum’s 136-year history, but in 2025, the museum will focus on the smaller things, both literally and ...

MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...